字幕表 動画を再生する 英語字幕をプリント RESOURCES RESOURCES AND RESOURCES AND AS RESOURCES AND AS OF RESOURCES AND AS OF TODAY RESOURCES AND AS OF TODAY CORONAVIRUS RESOURCES AND AS OF TODAY CORONAVIRUS HAS RESOURCES AND AS OF TODAY CORONAVIRUS HAS BEEN RESOURCES AND AS OF TODAY CORONAVIRUS HAS BEEN TO RESOURCES AND AS OF TODAY CORONAVIRUS HAS BEEN TO 18 CORONAVIRUS HAS BEEN TO 18 CORONAVIRUS HAS BEEN TO 18 COUNTRIES. COUNTRIES. COUNTRIES. GEORGIA4@ COUNTRIES. GEORGIA4@ IS COUNTRIES. GEORGIA4@ IS A COUNTRIES. GEORGIA4@ IS A PART COUNTRIES. GEORGIA4@ IS A PART OF COUNTRIES. GEORGIA4@ IS A PART OF THE COUNTRIES. GEORGIA4@ IS A PART OF THE RACE COUNTRIES. GEORGIA4@ IS A PART OF THE RACEO GEORGIA4@ IS A PART OF THE RACEO GEORGIA4@ IS A PART OF THE RACEO DEVELOP GEORGIA4@ IS A PART OF THE RACEO DEVELOP A GEORGIA4@ IS A PART OF THE RACEO DEVELOP A VACCINE GEORGIA4@ IS A PART OF THE RACEO DEVELOP A VACCINE AND GEORGIA4@ IS A PART OF THE RACEO DEVELOP A VACCINE AND DEKALB DEVELOP A VACCINE AND DEKALB DEVELOP A VACCINE AND DEKALB COUNTY DEVELOP A VACCINE AND DEKALB COUNTY COMPANY DEVELOP A VACCINE AND DEKALB COUNTY COMPANY BELIEVES DEVELOP A VACCINE AND DEKALB COUNTY COMPANY BELIEVES IT DEVELOP A VACCINE AND DEKALB COUNTY COMPANY BELIEVES IT HAS COUNTY COMPANY BELIEVES IT HAS COUNTY COMPANY BELIEVES IT HAS AN COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE BECAUSE COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE BECAUSE IT COUNTY COMPANY BELIEVES IT HAS AN ADVANTAGE BECAUSE IT HAS AN ADVANTAGE BECAUSE IT HAS AN ADVANTAGE BECAUSE IT HAS QUITE AN ADVANTAGE BECAUSE IT HAS QUITE A AN ADVANTAGE BECAUSE IT HAS QUITE A LONG AN ADVANTAGE BECAUSE IT HAS QUITE A LONG TRACK AN ADVANTAGE BECAUSE IT HAS QUITE A LONG TRACK RECORD. QUITE A LONG TRACK RECORD. QUITE A LONG TRACK RECORD. >> QUITE A LONG TRACK RECORD. >> WE QUITE A LONG TRACK RECORD. >> WE WANTED QUITE A LONG TRACK RECORD. >> WE WANTED TO QUITE A LONG TRACK RECORD. >> WE WANTED TO LEARN QUITE A LONG TRACK RECORD. >> WE WANTED TO LEARN MORE >> WE WANTED TO LEARN MORE >> WE WANTED TO LEARN MORE ABOUT >> WE WANTED TO LEARN MORE ABOUT THE >> WE WANTED TO LEARN MORE ABOUT THE PROCESS >> WE WANTED TO LEARN MORE ABOUT THE PROCESS AND >> WE WANTED TO LEARN MORE ABOUT THE PROCESS AND JOE >> WE WANTED TO LEARN MORE ABOUT THE PROCESS AND JOE HENKE ABOUT THE PROCESS AND JOE HENKE ABOUT THE PROCESS AND JOE HENKE STOPPED ABOUT THE PROCESS AND JOE HENKE STOPPED BY ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR A ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR A LAB ABOUT THE PROCESS AND JOE HENKE STOPPED BY FOR A LAB REPORT. STOPPED BY FOR A LAB REPORT. STOPPED BY FOR A LAB REPORT. >> STOPPED BY FOR A LAB REPORT. >> Reporter: STOPPED BY FOR A LAB REPORT. >> Reporter: CURRENTLY STOPPED BY FOR A LAB REPORT. >> Reporter: CURRENTLY A STOPPED BY FOR A LAB REPORT. >> Reporter: CURRENTLY A RISK >> Reporter: CURRENTLY A RISK >> Reporter: CURRENTLY A RISK OF >> Reporter: CURRENTLY A RISK OF VACCINES >> Reporter: CURRENTLY A RISK OF VACCINES FOR >> Reporter: CURRENTLY A RISK OF VACCINES FOR THE >> Reporter: CURRENTLY A RISK OF VACCINES FOR THE VIRUS >> Reporter: CURRENTLY A RISK OF VACCINES FOR THE VIRUS IS OF VACCINES FOR THE VIRUS IS OF VACCINES FOR THE VIRUS IS BEING OF VACCINES FOR THE VIRUS IS BEING TESTED OF VACCINES FOR THE VIRUS IS BEING TESTED OR OF VACCINES FOR THE VIRUS IS BEING TESTED OR READY OF VACCINES FOR THE VIRUS IS BEING TESTED OR READY TO OF VACCINES FOR THE VIRUS IS BEING TESTED OR READY TO BE BEING TESTED OR READY TO BE BEING TESTED OR READY TO BE TESTED BEING TESTED OR READY TO BE TESTED AND BEING TESTED OR READY TO BE TESTED AND SOME4@ BEING TESTED OR READY TO BE TESTED AND SOME4@ ARE BEING TESTED OR READY TO BE TESTED AND SOME4@ ARE VIRUSES TESTED AND SOME4@ ARE VIRUSES TESTED AND SOME4@ ARE VIRUSES SIMILAR TESTED AND SOME4@ ARE VIRUSES SIMILAR TO TESTED AND SOME4@ ARE VIRUSES SIMILAR TO CORONAVIRUS TESTED AND SOME4@ ARE VIRUSES SIMILAR TO CORONAVIRUS WHICH SIMILAR TO CORONAVIRUS WHICH SIMILAR TO CORONAVIRUS WHICH COULD SIMILAR TO CORONAVIRUS WHICH COULD SPEED SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP THE SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP THE PROCESS SIMILAR TO CORONAVIRUS WHICH COULD SPEED UP THE PROCESS AND COULD SPEED UP THE PROCESS AND COULD SPEED UP THE PROCESS AND SOME COULD SPEED UP THE PROCESS AND SOME WHO COULD SPEED UP THE PROCESS AND SOME WHO HAS COULD SPEED UP THE PROCESS AND SOME WHO HAS SIX COULD SPEED UP THE PROCESS AND SOME WHO HAS SIX EXISTING SOME WHO HAS SIX EXISTING SOME WHO HAS SIX EXISTING RELATIONSHIPS SOME WHO HAS SIX EXISTING RELATIONSHIPS WITH SOME WHO HAS SIX EXISTING RELATIONSHIPS WITH HEALTH SOME WHO HAS SIX EXISTING RELATIONSHIPS WITH HEALTH 4@ RELATIONSHIPS WITH HEALTH 4@ RELATIONSHIPS WITH HEALTH 4@ OFFICIALS RELATIONSHIPS WITH HEALTH 4@ OFFICIALS DOESN'T RELATIONSHIPS WITH HEALTH 4@ OFFICIALS DOESN'T HURT4@ RELATIONSHIPS WITH HEALTH 4@ OFFICIALS DOESN'T HURT4@ EITHER OFFICIALS DOESN'T HURT4@ EITHER OFFICIALS DOESN'T HURT4@ EITHER >> OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: SCIENTISTS OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: SCIENTISTS LIKE OFFICIALS DOESN'T HURT4@ EITHER >> Reporter: SCIENTISTS LIKE RV >> Reporter: SCIENTISTS LIKE RV >> Reporter: SCIENTISTS LIKE RV INFECT >> Reporter: SCIENTISTS LIKE RV INFECT CELLS >> Reporter: SCIENTISTS LIKE RV INFECT CELLS IN >> Reporter: SCIENTISTS LIKE RV INFECT CELLS IN VIRUSES >> Reporter: SCIENTISTS LIKE RV INFECT CELLS IN VIRUSES THEY INFECT CELLS IN VIRUSES THEY INFECT CELLS IN VIRUSES THEY ARE INFECT CELLS IN VIRUSES THEY ARE SETTING INFECT CELLS IN VIRUSES THEY ARE SETTING AND INFECT CELLS IN VIRUSES THEY ARE SETTING AND USE INFECT CELLS IN VIRUSES THEY ARE SETTING AND USE THEIR ARE SETTING AND USE THEIR ARE SETTING AND USE THEIR FINDINGS ARE SETTING AND USE THEIR FINDINGS AS4@ ARE SETTING AND USE THEIR FINDINGS AS4@ THEY ARE SETTING AND USE THEIR FINDINGS AS4@ THEY DEVELOP FINDINGS AS4@ THEY DEVELOP FINDINGS AS4@ THEY DEVELOP VACCINES. VACCINES. VACCINES. THEY VACCINES. THEY USE VACCINES. THEY USE AN VACCINES. THEY USE AN APPROACH VACCINES. THEY USE AN APPROACH THAT VACCINES. THEY USE AN APPROACH THAT THE THEY USE AN APPROACH THAT THE THEY USE AN APPROACH THAT THE CEO THEY USE AN APPROACH THAT THE CEO SAYS THEY USE AN APPROACH THAT THE CEO SAYS IT THEY USE AN APPROACH THAT THE CEO SAYS IT IS THEY USE AN APPROACH THAT THE CEO SAYS IT IS EFFICIENT THEY USE AN APPROACH THAT THE CEO SAYS IT IS EFFICIENT IN CEO SAYS IT IS EFFICIENT IN CEO SAYS IT IS EFFICIENT IN CREATING CEO SAYS IT IS EFFICIENT IN CREATING A CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE TO CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE TO BE CEO SAYS IT IS EFFICIENT IN CREATING A VACCINE TO BE TESTED CREATING A VACCINE TO BE TESTED CREATING A VACCINE TO BE TESTED AND CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS IT CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS IT MAKES CREATING A VACCINE TO BE TESTED AND 4@EFFECTIVE AS IT MAKES A AND 4@EFFECTIVE AS IT MAKES A AND 4@EFFECTIVE AS IT MAKES A VACCINE AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A SINGLE AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A SINGLE DOSE AND 4@EFFECTIVE AS IT MAKES A VACCINE THAT'S A SINGLE DOSE AND VACCINE THAT'S A SINGLE DOSE AND VACCINE THAT'S A SINGLE DOSE AND SET VACCINE THAT'S A SINGLE DOSE AND SET OF VACCINE THAT'S A SINGLE DOSE AND SET OF MULTIPLE VACCINE THAT'S A SINGLE DOSE AND SET OF MULTIPLE DOSES. SET OF MULTIPLE DOSES. SET OF MULTIPLE DOSES. GENERALLY SET OF MULTIPLE DOSES. GENERALLY THEY SET OF MULTIPLE DOSES. GENERALLY THEY CAN SET OF MULTIPLE DOSES. GENERALLY THEY CAN CREATE SET OF MULTIPLE DOSES. GENERALLY THEY CAN CREATE A GENERALLY THEY CAN CREATE A GENERALLY THEY CAN CREATE A BASIS GENERALLY THEY CAN CREATE A BASIS FOR GENERALLY THEY CAN CREATE A BASIS FOR A GENERALLY THEY CAN CREATE A BASIS FOR A VACCINE GENERALLY THEY CAN CREATE A BASIS FOR A VACCINE WITHIN BASIS FOR A VACCINE WITHIN BASIS FOR A VACCINE WITHIN THREE BASIS FOR A VACCINE WITHIN THREE MONTHS BASIS FOR A VACCINE WITHIN THREE MONTHS AND BASIS FOR A VACCINE WITHIN THREE MONTHS AND BEGIN BASIS FOR A VACCINE WITHIN THREE MONTHS AND BEGIN ANIMAL THREE MONTHS AND BEGIN ANIMAL THREE MONTHS AND BEGIN ANIMAL TESTING. TESTING. TESTING. >> TESTING. >> GOING TESTING. >> GOING BEYOND TESTING. >> GOING BEYOND THAT TESTING. >> GOING BEYOND THAT IN TESTING. >> GOING BEYOND THAT IN THE >> GOING BEYOND THAT IN THE >> GOING BEYOND THAT IN THE CLINICAL >> GOING BEYOND THAT IN THE CLINICAL IS >> GOING BEYOND THAT IN THE CLINICAL IS A >> GOING BEYOND THAT IN THE CLINICAL IS A FUNCTION >> GOING BEYOND THAT IN THE CLINICAL IS A FUNCTION OF >> GOING BEYOND THAT IN THE CLINICAL IS A FUNCTION OF WHAT CLINICAL IS A FUNCTION OF WHAT CLINICAL IS A FUNCTION OF WHAT REGULATORY CLINICAL IS A FUNCTION OF WHAT REGULATORY AUTHORITIES REGULATORY AUTHORITIES REGULATORY AUTHORITIES DETERMINE REGULATORY AUTHORITIES DETERMINE WHAT REGULATORY AUTHORITIES DETERMINE WHAT IS REGULATORY AUTHORITIES DETERMINE WHAT IS APPROPRIATE DETERMINE WHAT IS APPROPRIATE DETERMINE WHAT IS APPROPRIATE PROTOCOL DETERMINE WHAT IS APPROPRIATE PROTOCOL TO DETERMINE WHAT IS APPROPRIATE PROTOCOL TO FOLLOW DETERMINE WHAT IS APPROPRIATE PROTOCOL TO FOLLOW AND PROTOCOL TO FOLLOW AND PROTOCOL TO FOLLOW AND DEPENDING PROTOCOL TO FOLLOW AND DEPENDING ON PROTOCOL TO FOLLOW AND DEPENDING ON THAT PROTOCOL TO FOLLOW AND DEPENDING ON THAT THAT PROTOCOL TO FOLLOW AND DEPENDING ON THAT THAT WILL DEPENDING ON THAT THAT WILL DEPENDING ON THAT THAT WILL DETERMINE DEPENDING ON THAT THAT WILL DETERMINE HOW DEPENDING ON THAT THAT WILL DETERMINE HOW IT DEPENDING ON THAT THAT WILL DETERMINE HOW IT WILL DEPENDING ON THAT THAT WILL DETERMINE HOW IT WILL GO DEPENDING ON THAT THAT WILL DETERMINE HOW IT WILL GO TO DETERMINE HOW IT WILL GO TO DETERMINE HOW IT WILL GO TO HUMANS. HUMANS. HUMANS. >> HUMANS. >> 4@THEY HUMANS. >> 4@THEY HAVE HUMANS. >> 4@THEY HAVE VACCINES HUMANS. >> 4@THEY HAVE VACCINES FOR HUMANS. >> 4@THEY HAVE VACCINES FOR OTH >> 4@THEY HAVE VACCINES FOR OTH >> 4@THEY HAVE VACCINES FOR OTH VIRUSES >> 4@THEY HAVE VACCINES FOR OTH VIRUSES AND >> 4@THEY HAVE VACCINES FOR OTH VIRUSES AND VACCINES >> 4@THEY HAVE VACCINES FOR OTH VIRUSES AND VACCINES ENTRY VIRUSES AND VACCINES ENTRY VIRUSES AND VACCINES ENTRY CLINICAL VIRUSES AND VACCINES ENTRY CLINICAL CLOUD VIRUSES AND VACCINES ENTRY CLINICAL CLOUD TILES. CLINICAL CLOUD TILES. CLINICAL CLOUD TILES. WITH CLINICAL CLOUD TILES. WITH THE CLINICAL CLOUD TILES. WITH THE CORONAVIRUS CLINICAL CLOUD TILES. WITH THE CORONAVIRUS TIME CLINICAL CLOUD TILES. WITH THE CORONAVIRUS TIME IS CLINICAL CLOUD TILES. WITH THE CORONAVIRUS TIME IS OF WITH THE CORONAVIRUS TIME IS OF WITH THE CORONAVIRUS TIME IS OF THE WITH THE CORONAVIRUS TIME IS OF THE ESSENCE WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND THEY WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND THEY CAN WITH THE CORONAVIRUS TIME IS OF THE ESSENCE AND THEY CAN USE THE ESSENCE AND THEY CAN USE THE ESSENCE AND THEY CAN USE RESEARCH. RESEARCH. RESEARCH. >> RESEARCH. >> THIS RESEARCH. >> THIS VIRUS RESEARCH. >> THIS VIRUS IS RESEARCH. >> THIS VIRUS IS SIMILAR RESEARCH. >> THIS VIRUS IS SIMILAR TO >> THIS VIRUS IS SIMILAR TO >> THIS VIRUS IS SIMILAR TO SARS >> THIS VIRUS IS SIMILAR TO SARS 4@AND >> THIS VIRUS IS SIMILAR TO SARS 4@AND WE >> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN >> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN BUILD >> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN BUILD UPON >> THIS VIRUS IS SIMILAR TO SARS 4@AND WE CAN BUILD UPON TH SARS 4@AND WE CAN BUILD UPON TH SARS 4@AND WE CAN BUILD UPON TH FOUNDATION SARS 4@AND WE CAN BUILD UPON TH FOUNDATION OF SARS 4@AND WE CAN BUILD UPON TH FOUNDATION OF LITERATURE SARS 4@AND WE CAN BUILD UPON TH FOUNDATION OF LITERATURE THAT FOUNDATION OF LITERATURE THAT FOUNDATION OF LITERATURE THAT EXISTS FOUNDATION OF LITERATURE THAT EXISTS PERTAINING FOUNDATION OF LITERATURE THAT EXISTS PERTAINING TO EXISTS PERTAINING TO EXISTS PERTAINING TO DEVELOPMENT EXISTS PERTAINING TO DEVELOPMENT OF EXISTS PERTAINING TO DEVELOPMENT OF THE EXISTS PERTAINING TO DEVELOPMENT OF THE SARS EXISTS PERTAINING TO DEVELOPMENT OF THE SARS VACCINE DEVELOPMENT OF THE SARS VACCINE DEVELOPMENT OF THE SARS VACCINE AND DEVELOPMENT OF THE SARS VACCINE AND APPLY DEVELOPMENT OF THE SARS VACCINE AND APPLY IT DEVELOPMENT OF THE SARS VACCINE AND APPLY IT FOR DEVELOPMENT OF THE SARS VACCINE AND APPLY IT FOR THIS DEVELOPMENT OF THE SARS VACCINE AND APPLY IT FOR THIS OUTBREAK. AND APPLY IT FOR THIS OUTBREAK. AND APPLY IT FOR THIS OUTBREAK. >>4@ AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING ALONGSIDE AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING ALONGSIDE THEM AND APPLY IT FOR THIS OUTBREAK. >>4@ WORKING ALONGSIDE THEM IS >>4@ WORKING ALONGSIDE THEM IS >>4@ WORKING ALONGSIDE THEM IS BRAVO >>4@ WORKING ALONGSIDE THEM IS BRAVO MAX >>4@ WORKING ALONGSIDE THEM IS BRAVO MAX ARE >>4@ WORKING ALONGSIDE THEM IS BRAVO MAX ARE WUHAN >>4@ WORKING ALONGSIDE THEM IS BRAVO MAX ARE WUHAN VACCINE BRAVO MAX ARE WUHAN VACCINE BRAVO MAX ARE WUHAN VACCINE DEVELOPER BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN THE BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN THE EPICENTER BRAVO MAX ARE WUHAN VACCINE DEVELOPER IN THE EPICENTER OF DEVELOPER IN THE EPICENTER OF DEVELOPER IN THE EPICENTER OF THE DEVELOPER IN THE EPICENTER OF THE OUTBREAK. THE OUTBREAK. THE OUTBREAK. THEY4@ THE OUTBREAK. THEY4@ ENTERED THE OUTBREAK. THEY4@ ENTERED AN THE OUTBREAK. THEY4@ ENTERED AN AGREEMENT THE OUTBREAK. THEY4@ ENTERED AN AGREEMENT TO THEY4@ ENTERED AN AGREEMENT TO THEY4@ ENTERED AN AGREEMENT TO CREATE THEY4@ ENTERED AN AGREEMENT TO CREATE A THEY4@ ENTERED AN AGREEMENT TO CREATE A VACCINE. CREATE A VACCINE. CREATE A VACCINE. >> CREATE A VACCINE. >> THEY CREATE A VACCINE. >> THEY HAVE CREATE A VACCINE. >> THEY HAVE A CREATE A VACCINE. >> THEY HAVE A STRONG >> THEY HAVE A STRONG >> THEY HAVE A STRONG RELATIONSHIP >> THEY HAVE A STRONG RELATIONSHIP WITH >> THEY HAVE A STRONG RELATIONSHIP WITH THE >> THEY HAVE A STRONG RELATIONSHIP WITH THE CHINESE RELATIONSHIP WITH THE CHINESE RELATIONSHIP WITH THE CHINESE CDC RELATIONSHIP WITH THE CHINESE CDC AND RELATIONSHIP WITH THE CHINESE CDC AND THE RELATIONSHIP WITH THE CHINESE CDC AND THE CHINESE RELATIONSHIP WITH THE CHINESE CDC AND THE CHINESE PUBLIC CDC AND THE CHINESE PUBLIC CDC AND THE CHINESE PUBLIC REGULATORY CDC AND THE CHINESE PUBLIC REGULATORY OFFICIALS. REGULATORY OFFICIALS. REGULATORY OFFICIALS. AND REGULATORY OFFICIALS. AND WORKING REGULATORY OFFICIALS. AND WORKING TOGETHER REGULATORY OFFICIALS. AND WORKING TOGETHER WE REGULATORY OFFICIALS. AND WORKING TOGETHER WE THINK AND WORKING TOGETHER WE THINK AND WORKING TOGETHER WE THINK WE AND WORKING TOGETHER WE THINK WE CAN AND WORKING TOGETHER WE THINK WE CAN MOVE AND WORKING TOGETHER WE THINK WE CAN MOVE MUCH AND WORKING TOGETHER WE THINK WE CAN MOVE MUCH QUICKER AND WORKING TOGETHER WE THINK WE CAN MOVE MUCH QUICKER ALONG WE CAN MOVE MUCH QUICKER ALONG WE CAN MOVE MUCH QUICKER ALONG WITH WE CAN MOVE MUCH QUICKER ALONG WITH THE WE CAN MOVE MUCH QUICKER ALONG WITH THE OTHER WE CAN MOVE MUCH QUICKER ALONG WITH THE OTHER ENTITIES WE CAN MOVE MUCH QUICKER ALONG WITH THE OTHER ENTITIES WE WITH THE OTHER ENTITIES WE WITH THE OTHER ENTITIES WE BROUGHT WITH THE OTHER ENTITIES WE BROUGHT IN WITH THE OTHER ENTITIES WE BROUGHT IN WITH WITH THE OTHER ENTITIES WE BROUGHT IN WITH A WITH THE OTHER ENTITIES WE BROUGHT IN WITH A CANDIDATE WITH THE OTHER ENTITIES WE BROUGHT IN WITH A CANDIDATE FOR BROUGHT IN WITH A CANDIDATE FOR BROUGHT IN WITH A CANDIDATE FOR TESTING. TESTING. TESTING. >> TESTING. >> I'M TESTING. >> I'M TOLD TESTING. >> I'M TOLD THE TESTING. >> I'M TOLD THE TIMELINE TESTING. >> I'M TOLD THE TIMELINE FOR >> I'M TOLD THE TIMELINE FOR >> I'M TOLD THE TIMELINE FOR THE >> I'M TOLD THE TIMELINE FOR THE VACCINE >> I'M TOLD THE TIMELINE FOR THE VACCINE COULD >> I'M TOLD THE TIMELINE FOR THE VACCINE COULD BE >> I'M TOLD THE TIMELINE FOR THE VACCINE COULD BE READY. THE VACCINE COULD BE READY. THE VACCINE COULD BE READY. IT THE VACCINE COULD BE READY. IT COULD THE VACCINE COULD BE READY. IT COULD BE THE VACCINE COULD BE READY. IT COULD BE MONTHS THE VACCINE COULD BE READY. IT COULD BE MONTHS OR THE VACCINE COULD BE READY. IT COULD BE MONTHS OR MORE THE VACCINE COULD BE READY. IT COULD BE MONTHS OR MORE THAN IT COULD BE MONTHS OR MORE THAN IT COULD BE MONTHS OR MORE THAN 1 IT COULD BE MONTHS OR MORE THAN 1 YEAR. IT COULD BE MONTHS OR MORE THAN 1 YEAR. 4@ 1 YEAR. 4@ 1 YEAR. 4@ THE 1 YEAR. 4@ THE LARGEST 1 YEAR. 4@ THE LARGEST UNKNOWN 1 YEAR. 4@ THE LARGEST UNKNOWN IS 1 YEAR. 4@ THE LARGEST UNKNOWN IS HOW 1 YEAR. 4@ THE LARGEST UNKNOWN IS HOW LONG THE LARGEST UNKNOWN IS HOW LONG THE LARGEST UNKNOWN IS HOW LONG IT THE LARGEST UNKNOWN IS HOW LONG IT WILL THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE TO THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE TO SEEK THE LARGEST UNKNOWN IS HOW LONG IT WILL TAKE TO SEEK 4@4@GOVERN IT WILL TAKE TO SEEK 4@4@GOVERN IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE THE IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE THE VACCINE IT WILL TAKE TO SEEK 4@4@GOVERN APPROVAL TO USE THE VACCINE ON APPROVAL TO USE THE VACCINE ON APPROVAL TO USE THE VACCINE ON HUMANS. HUMANS. HUMANS. >>> HUMANS. >>> THERE HUMANS. >>> THERE ARE HUMANS. >>> THERE ARE A HUMANS. >>> THERE ARE A LOT HUMANS. >>> THERE ARE A LOT OF HUMANS. >>> THERE ARE A LOT OF STORIES >>> THERE ARE A LOT OF STORIES >>> THERE ARE A LOT OF STORIES CIRCULATING >>> THERE ARE A LOT OF STORIES CIRCULATING ABOUT >>> THERE ARE A LOT OF STORIES CIRCULATING ABOUT THE CIRCULATING ABOUT THE CIRCULATING ABOUT THE CORONAVIRUS CIRCULATING ABOUT THE CORONAVIRUS AND CIRCULATING ABOUT THE CORONAVIRUS AND MANY CIRCULATING ABOUT THE CORONAVIRUS AND MANY ARE CIRCULATING ABOUT THE CORONAVIRUS AND MANY ARE NOT CORONAVIRUS AND MANY ARE NOT
B2 中上級 新型コロナウイルス 新型肺炎 COVID-19 メトロアトランタの企業がコロナウイルスワクチンの開発競争に参加 (Metro Atlanta company joins race to develop coronavirus vaccine) 8 0 林宜悉 に公開 2021 年 01 月 14 日 シェア シェア 保存 報告 動画の中の単語